TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31258919
Drug: Vilanterol 25
Normalized name: FLUTIC 50/VILANTEROL 25MCG 30D ORAL INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol 25 µg (VI)
Study: 31258919
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 µg (FF)
Study: 31258919
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vilanterol 25 µg and Fluticasone furoate 100 µg (VI 25/FF 100)
Study: 9576452
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 gm b.i.d.)
Study: 9576452
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (lansoprazole t.i.d. and amoxicillin t.i.d.)
Study: 9576452
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (lansoprazole b.i.d. and clarithromycin t.i.d.)
Study: 9576452
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (lansoprazole b.i.d. and clarithromycin b.i.d.)
Study: 9576452
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (lansoprazole b.i.d. and amoxicillin t.i.d.)
Study: 9576452
Drug: Monotherapy (lansoprazole)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (lansoprazole)
Study: 9576452
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy and dual therapy
Study: 7887102
Drug: Patient‐controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient‐controlled intravenous morphine
Study: 21498100
Drug: GH receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH receptor blocker (pegvisomant, 5 mg/day, n=9)
Study: 12679756
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH, 5000 IU 3 times daily)
Study: 10858919
Drug: Sulbutiamine (Arcalion)
Normalized name: sulbutiamine
DrugBank: Sulbutiamine (DB13416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbutiamine (Arcalion) 600 mg p.d.
Study: 2405042
Drug: Injections every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections every 3 months (21 patients)
Study: 2405042
Drug: Injections every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections every 6 weeks (22 patients)
Study: 28509605
Drug: Bio Pox™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio Pox™ (indigenous investigational vaccine)
Study: 28509605
Drug: Varivax™ (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varivax™ (licensed vaccine)
Study: 23107810
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose triamcinolone acetate
Study: 23107810
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose triamcinolone acetate
Study: 16957432
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel 0.1% in combination with benzoyl peroxide/clindamycin
Study: 16957432
Drug: Tretinoin microsphere
Normalized name: tretinoin microsphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin microsphere 0.04% in combination with benzoyl peroxide/clindamycin
Study: 16957432
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream 0.05% in combination with benzoyl peroxide/clindamycin
Study: 15532202
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg, administered 1 hour before sleep for 28 days)
Study: 12629445
Drug: Losartan therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan therapy
Study: 9266391
Drug: Oral uridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral uridine powder at 150 mg/kg per day (divided dose, three times daily)
Study: 9266391
Drug: Uridine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uridine treatment started prior to age 14 months
Study: 7884218
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of intravenous ceftriaxone alone
Study: 7884218
Drug: Successful treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful treatments
Study: 2455152
Drug: Enalaprilat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (5 mg i.v.)
Study: 29475056
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy protocol for the prevention of suicide
Study: 27595681
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 100 mg once daily
Study: 20961244
Drug: Weekly self-testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly self-testing at home
Study: 20961244
Drug: Monthly high-quality
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly high-quality testing in a clinic
Study: 18178039
Drug: Triazolam 0.25
Normalized name: triazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.25 mg/70 kg
Study: 18178039
Drug: Triazolam 0.12
Normalized name: triazolam 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.12 mg/70 kg
Study: 18178039
Drug: Triazolam (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (various doses: 0.00, 0.06, 0.12, and 0.25 mg/70 kg)
Study: 16189252
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor letrozole (Lz; 2.5 mg/d)
Study: 8666320
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (control group, n = 31)
Study: 20437076
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (n = 15)
Study: 20437076
Drug: Sham vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham vaccine (n = 9)
Study: 17549475
Drug: PLD 60
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 60 mg/m² (1st cycle), 30 mg/m² (2nd cycle), 45 mg/m² (3rd cycle)
Study: 17549475
Drug: PLD 30
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 30 mg/m² (1st cycle), 60 mg/m² (2nd cycle), 45 mg/m² (3rd cycle)
Study: 17549475
Drug: PLD (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD (all doses across cycles)
Study: 10863615
Drug: Amodiaquine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (35 mg/kg over 3 days: 1st day: 15 mg/kg; 2nd day: 10 mg/kg; 3rd day: 10 mg/kg)
Study: 10863615
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (self-medication)
Study: 8779379
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg (Groups B, C, D, E, F)
Study: 10736983
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/die)
Study: 2699465
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg/die)
Study: 7494563
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m²) + Paclitaxel (135 mg/m² over 24 hours)
Study: 7494563
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m²) + Cyclophosphamide (750 mg/m²)
Study: 3893039
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g acetylsalicylic acid (ASA) for two days
Study: 31805012
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg NAC BID for 12 weeks then TID for 12 weeks
Study: 31805012
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg NAC BID for 12 weeks then TID for 12 weeks
Study: 31805012
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg NAC BID for 12 weeks then TID for 12 weeks
Study: 30376082
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of IPV doses
Study: 22633184
Drug: 2-titration group
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2-titration group
Study: 22633184
Drug: Single-titration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-titration group
Study: 18164168
Drug: Debiasing technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debiasing technique (participants listing advantages and disadvantages of each treatment)
Study: 12118746
Drug: Heparin bonded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bonded extracorporeal circuits (group H)
Study: 10094133
Drug: Serotonin 2A
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin 2A receptor variant (102T/C) in schizophrenic patients
Study: 10094133
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment in schizophrenic patients
Study: 2139241
Drug: McKenzie method
Approvals — FDA: no, EMA: no, PMDA: no
Description: McKenzie method of treatment
Study: 2103969
Drug: Heparin-glucuronilglucosaminoglycane treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-glucuronilglucosaminoglycane treatment
Study: 7408684
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acebutolol (Prent)
Study: 28697113
Drug: Paracervical block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical block with 18 mL 1% lidocaine and 2 mL sodium bicarbonate
Study: 23463624
Drug: Capecitabine and
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and oral cyclophosphamide (CCy)
Study: 20813884
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 μg plus fluticasone propionate 500 μg, twice a day
Study: 19481079
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EVL, propranolol (dose titrated to reduce heart rate to 55 bpm), and ISMN (40 mg/day)
Study: 19481079
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EVL, propranolol, and ISMN
Study: 19481079
Drug: Cirrhotic patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cirrhotic patients in combination group
Study: 11916195
Drug: Ropivacaine gel
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine gel (200 mg)
Study: 10414879
Drug: Interferon-alpha2a (9MU/d)
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2a (9MU/d) + zidovudine (2x250 mg/d)
Study: 10414879
Drug: Bleomycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (15 mg every 2 weeks) + zidovudine (2x250 mg/d)
Study: 6778187
Drug: Tocainide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (750 mg i.v. during a 15-minute period followed by 800 mg orally and later 400 mg t.i.d.)
Study: 25645168
Drug: Therapist-guided internet-delivered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided internet-delivered cognitive behavior therapy (iCBT)
Study: 24025143
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ornithine aspartate plus naloxone
Study: 24025143
Drug: Traditional medical
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medical treatment
Study: 21429443
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg/1 ml
Study: 21429443
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg/3 ml
Study: 11430960
Drug: Other tocolytic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other tocolytic agents
Study: 2514653
Drug: Cicletanine 150-200
Normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 150-200 mg/day
Study: 4393354
Drug: Propranolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (5 to 1,280 mg orally)
Study: 4393354
Drug: Sotalol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (5 to 1,280 mg orally)
Study: 4393354
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (no drug)
Study: 14756610
Drug: Cognitive trauma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive trauma therapy for battered women with PTSD (CTT-BW)
Study: 11177402
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and didanosine (dual therapy)
Study: 11177402
Drug: Zidovudine, didanosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, didanosine, and lamivudine (triple therapy)
Study: 9638980
Drug: Normal-risk group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-risk group receiving CHOP chemotherapy
Study: 9638980
Drug: High-risk patients
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk patients treated with low-dose CHOP
Study: 9638980
Drug: Normal-risk patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-risk patients during chemotherapy
Study: 8091999
Drug: Depot antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot antipsychotic medication during the initial 1-year period
Study: 31178096
Drug: Medication-free period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free period
Study: 2694767
Drug: Maintenance antipsychotic
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance antipsychotic medication
Study: 2734719
Drug: Antacid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid treatment (Rocgel)
Study: 23786821
Drug: Buttermilk (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buttermilk (45 g/d)
Study: 23786821
Drug: Placebo (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (45 g/d)
Study: 16001993
Drug: PLD 50
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 50 mg/m2 I.V. on day 1 and cyclophosphamide 100 mg/m2 orally on days 1‐14 every 28‐day cycle
Study: 16001993
Drug: PLD 30
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 30 mg/m2 plus cyclophosphamide 600 mg/m2 I.V. on day 1 every 21 days
Study: 16001993
Drug: PLD 35
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 35 mg/m2 plus cyclophosphamide 600 mg/m2 I.V. on day 1 every 21 days
Study: 3050905
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg preoperatively
Study: 25782644
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg escitalopram daily from preanesthesia to postoperative day 6
Study: 25782644
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily from preanesthesia to postoperative day 6
Study: 19531592
Drug: PPAR alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPAR alpha agonist (20 microg/d GW590735)
Study: 19531592
Drug: PPAR delta
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPAR delta agonist (10 mg/d GW501516)
Study: 19531592
Drug: PPAR gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPAR gamma agonist (rosiglitazone)
Study: 17569044
Drug: Vinorelbine (VRL)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (VRL) 20 mg m(‐2) i.v. on day 1, Docetaxel (DCT) 60 mg m(‐2) on day 1, Oral VRL 60 mg m(‐2) on day 15 every 3 weeks
Study: 17569044
Drug: Vinorelbine (VRL)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (VRL) 20 mg m(‐2) i.v. with Docetaxel (DCT) 60 mg m(‐2) on day 1, Oral VRL 60 mg m(‐2) on day 15 every 3 weeks
Study: 11208496
Drug: Drug I
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug I (propafenone, sotalol, or disopyramide)
Study: 11208496
Drug: Drug II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug II (second antiarrhythmic drug)
Study: 11208496
Drug: Amiodarone (Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (Drug III)
Study: 30369161
Drug: Ningmitai capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningmitai capsules (4 capsules per time, 3 times per day)
Study: 30369161
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibiotics or sodium diclofenac suppository on demand)
Study: 27898683
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug use, polysubstance use, environmental risk exposures (past incarceration, police involvement, selling sex, HIV stigma)
Study: 22421008
Drug: 6-month therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-month therapy group
Study: 22421008
Drug: 12-month therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-month therapy group
Study: 20167686
Drug: Increased water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased water intake of 3 L per day
Study: 19074351
Drug: Modafinil administration
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil administration
Study: 17190281
Drug: Topical nitroderivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroderivatives
Study: 8626044
Drug: Glycine-extended gastrin-17
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine-extended gastrin-17 infusion at three consecutive dose rates
Study: 8626044
Drug: Glycine-extended gastrin-17
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine-extended gastrin-17 infusion
Study: 8626044
Drug: Glycine-extended gastrin-17
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine-extended gastrin-17 infusion during constant-rate infusion after a protein meal
Study: 1575169
Drug: Quinapril, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril, 20 mg, administered in the evening (10 PM)
Study: 1575169
Drug: Quinapril, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril, 20 mg, administered in the morning (8 AM)
Study: 3918178
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 50 mg daily for 6 to 9 months
Study: 20713790
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of methylprednisolone
Study: 29872803
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g high MW (HMW) barley beta-glucan
Study: 29872803
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g low MW (LMW) barley beta-glucan
Study: 29872803
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g LMW barley beta-glucan
Study: 25254489
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of N-acetylcysteine (NAC) and saline
Study: 25254489
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (NAC and NaHCO3) and saline
Study: 9798043
Drug: Penicillin therapy
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin therapy (intramuscular benzylpenicillin, 50,000 U/[kg.d] for 5 days and then oral penicillin, 50 mg/[kg.d] for 5 days)
Study: 9798043
Drug: Erythromycin therapy
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin therapy (50 mg/[kg.d] orally for 10 days)
Study: 10921031
Drug: ATRA treatment
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA treatment
Study: 20496177
Drug: BAK-PLO (baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAK-PLO (baclofen 10 mg, amitriptyline HCL 40 mg, ketamine 20 mg in pluronic lecithin organogel)
Study: 19807931
Drug: Vaginal subcutaneous
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal subcutaneous injection of rhFSH (Puregon 300)
Study: 19807931
Drug: Abdominal subcutaneous
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal subcutaneous injection of rhFSH (Puregon 300)
Study: 18378608
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg BID
Study: 8465834
Drug: MRFIT hypertensive
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRFIT hypertensive patients with diuretic-based pharmacologic regimen